VivoSeq
Immunology

Pemphigus Vulgaris

26

Pipeline Programs↗

3

Active Trials↗

12

Companies Involved↗

Pemphigus Vulgaris is an emerging landscape with 26 programs across 12 companies. The most active players are Incyte, Principia Biopharma, a Sanofi Company, Immunex. 4 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

6/100

Mech. Concentration

31/100

Completion Rate

69/100

Attrition Rate

24/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Incyte logo

Incyte

1 program

Phase 2P

Principia Biopharma, a Sanofi Company

1 program

Phase 2I

Immunex

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals

1 program

Phase 3Novartis logo

Novartis

2 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

73%

Small molecule

19 of 26 classified programs — the dominant modality here.

27%ALL OTHERSMonoclonal antibody312%Protein / enzyme312%Cell therapy14%

Small molecule leads; the ring shows all 26 classified programs, each share of the total. Modality classified for 97% of 29 pipeline programs.

Analysis

Trial Status

21

clinical trials

Completed11 · 52%
Terminated4 · 19%
Unknown status2 · 10%
Recruiting2 · 10%
Withdrawn1 · 5%
Not yet recruiting1 · 5%

Clinical Trials

Trial Activity

21 trials

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
Recruiting·CCabaletta Bio·Phase 1/2·NCT04422912·40 enrolled
A Single-Arm, Open-Label Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CD19 CAR-T Cell Therapy in Patients With Moderate-to-Severe Refractory Pemphigus Vulgaris
Recruiting·—·Preclinical·NCT07681388·3 enrolled
Low-level Laser Therapy on Oral Pemphigus Vulgaris Patients.
Not yet recruiting·—·N/A·NCT06971172·22 enrolled
A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris
Completed·PPrincipia Biopharma, a Sanofi Company·Phase 2·NCT02704429·42 enrolled
Efficacy and Safety Evaluation of Anti-CD20 Monoclonal Antibody Combined with Azathioprine and Corticosteroids in the Treatment of Pemphigus Vulgaris
Completed·—·N/A·NCT06654817·38 enrolled
Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris
Completed·MMassachusetts General Hospital·Phase 2·NCT00135720·12 enrolled
Use of KC706 for the Treatment of Pemphigus Vulgaris
Completed·KKemia, Inc·Phase 2·NCT00606749·20 enrolled
Safety Study of PI-0824 to Treat Pemphigus Vulgaris
Completed·PPeptimmune·Phase 1·NCT00063752·15 enrolled
Use of Infliximab for the Treatment of Pemphigus Vulgaris
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00283712·20 enrolled
A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)
Completed·Roche logoRoche·Phase 3·NCT02383589·135 enrolled
Azathioprine Versus Placebo in Pemphigus Vulgaris Treated With Prednisolone
Completed·TTehran University of Medical Sciences·Phase 2·NCT00626678·48 enrolled
A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
Completed·Roche logoRoche·Phase 3·NCT00683930·96 enrolled
Comparing DCP and DAP for Pemphigus Vulgaris
Completed·JJinnah Postgraduate Medical Centre·Phase 4·NCT06846255·66 enrolled
Comparison Between Injections of Steroids and Autologous Platelet Rich Plasma in the Oral Erosions of Pemphigus Vulgaris
Completed·—·Phase 3·NCT02828163·11 enrolled
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
Terminated·Novartis logoNovartis·Phase 3·NCT01920477·35 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)